{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T10:31:39Z","timestamp":1782901899750,"version":"3.54.5"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T00:00:00Z","timestamp":1637193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Sanofi and conceived and conducted under the auspice of the Scientific Board by Laser"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>To evaluate the effectiveness and safety of dronedarone compared with other commonly used antiarrhythmic drugs (AADs) for preventing atrial fibrillation (AF) recurrences.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>An international observational cohort study in Germany, Spain, Italy, and the USA enrolling patients with AF receiving AAD therapy. Patients with New York Heart Association (NYHA) Class IV heart failure were excluded. Participants were followed for up to 18 months, regardless of discontinuation or subsequent AAD switches. Atrial fibrillation recurrence was captured by hospitalization, emergency room visit, or electrocardiogram-based documentation of AF. Confounding bias was controlled for in the analysis of AF recurrence using multivariate models of 19 variables for adjustment. A total of 1009 participants [mean age 67.2 (10.8) years, male to female ratio 1.3] were recruited from 170 centres, 693 (69%) of which were from across Europe and the remaining 316 (31%) from the USA. At the time of enrolment, participants were taking dronedarone (51%) or other AADs (49%) [flecainide or propafenone (42%), sotalol (11%), and amiodarone (47%)]. No significant differences in the risk of first confirmed AF recurrence with dronedarone vs. other AADs [crude hazard ratio (HR) 1.10 (95% confidence interval 0.85\u20131.42); adjusted HR 1.16 (0.87\u20131.55)] were found, irrespective of whether univariate or multivariate models were used. Reported safety events were in accordance with the known safety profile of dronedarone.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In this population of patients from either Europe or the USA receiving dronedarone or another AAD, the effectiveness of dronedarone was comparable to that observed for other AADs in preventing first AF recurrence.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/europace\/euab262","type":"journal-article","created":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T19:45:42Z","timestamp":1633549542000},"page":"899-909","source":"Crossref","is-referenced-by-count":14,"title":["International cohort study on the effectiveness of dronedarone and other antiarrhythmic drugs for atrial fibrillation in real-world practice (EFFECT-AF)"],"prefix":"10.1093","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3888-2347","authenticated-orcid":false,"given":"Artak","family":"Khachatryan","sequence":"first","affiliation":[{"name":"(Pharmaco)*Epidemiologist with Laser Group at Time of the Study , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1737-1903","authenticated-orcid":false,"given":"Jose L","family":"Merino","sequence":"additional","affiliation":[{"name":"University Hospital La Paz, Autonoma University, Arrhythmia & Robotic EP Unit, IdiPaz , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9119-8646","authenticated-orcid":false,"given":"Francisco Jose","family":"de Abajo","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, University Hospital Pr\u00edncipe de Asturias, Clinical Pharmacology Unit, University of Alcal\u00e1 (IRYCIS), Alcala de Henares , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8049-7517","authenticated-orcid":false,"given":"Giovanni L","family":"Botto","sequence":"additional","affiliation":[{"name":"ASST Rhodense, Rho & Garbagnate Hospitals, Head of Electrophysiology and Clinical Arrhythmology , Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1881-0197","authenticated-orcid":false,"given":"Paulus","family":"Kirchhof","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Heart and Vascular Centre UKE , Hamburg , Germany"},{"name":"German Centre for Cardiovascular Research (DZHK), Partner Site Hamburg\/Kiel\/L\u00fcbeck , Hamburg , Germany"},{"name":"University of Birmingham, Institute of Cardiovascular Sciences , Birmingham , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guenter","family":"Breithardt","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, University Hospital of Munster , Munster , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5692-2619","authenticated-orcid":false,"given":"Bruce","family":"Stambler","sequence":"additional","affiliation":[{"name":"Piedmont Heart Institute , Atlanta, GA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6106-9923","authenticated-orcid":false,"given":"Lucien","family":"Abenhaim","sequence":"additional","affiliation":[{"name":"Center for Risk Research CRRx Inc , Montreal , Canada"},{"name":"London School of Hygiene & Tropical Medicine , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1952-5467","authenticated-orcid":false,"given":"Lamiae","family":"Grimaldi-Bensouda","sequence":"additional","affiliation":[{"name":"Hospital Group Paris-Saclay, Assistance Publique- H\u00f4pitaux de Paris , Paris , France"},{"name":"Paris-Saclay University, INSERM, CESP Anti-Infective Evasion and Pharmacoepidemiology Team , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,11,18]]},"reference":[{"key":"2022071421521546600_euab262-B1","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"2022071421521546600_euab262-B2","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1056\/NEJMoa2019422","article-title":"Early rhythm-control therapy in patients with atrial fibrillation","volume":"383","author":"Kirchhof","year":"2020","journal-title":"N Engl J Med"},{"key":"2022071421521546600_euab262-B3","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.joad.2015.10.002","article-title":"A review on dronedarone: pharmacological, pharmacodynamic and pharmacokinetic profile","volume":"5","author":"Iram","year":"2016","journal-title":"J Acute Dis"},{"key":"2022071421521546600_euab262-B4","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/S0195-668X(03)00321-X","article-title":"Dronedarone for prevention of atrial fibrillation: a dose-ranging study","volume":"24","author":"Touboul","year":"2003","journal-title":"Eur Heart J"},{"key":"2022071421521546600_euab262-B5","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa054686","article-title":"Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter","volume":"357","author":"Singh","year":"2007","journal-title":"N Engl J Med"},{"key":"2022071421521546600_euab262-B6","doi-asserted-by":"crossref","first-page":"527.e1\u20139","DOI":"10.1016\/j.ahj.2008.06.010","article-title":"Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study","volume":"156","author":"Davy","year":"2008","journal-title":"Am Heart J"},{"key":"2022071421521546600_euab262-B7","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1056\/NEJMoa0803778","article-title":"Effect of dronedarone on cardiovascular events in atrial fibrillation","volume":"360","author":"Hohnloser","year":"2009","journal-title":"N Engl J Med"},{"key":"2022071421521546600_euab262-B8","author":"European Medicines Agency. Assessment report for Multaq","year":"2009"},{"key":"2022071421521546600_euab262-B9","author":"FDA.","year":"2009"},{"key":"2022071421521546600_euab262-B10","author":"FDA","year":"2012"},{"key":"2022071421521546600_euab262-B11","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1056\/NEJMoa1109867","article-title":"Dronedarone in high-risk permanent atrial fibrillation","volume":"365","author":"Connolly","year":"2011","journal-title":"N Engl J Med"},{"key":"2022071421521546600_euab262-B12","author":"Excellence","year":"2014"},{"key":"2022071421521546600_euab262-B13","author":"National Collaborating Centre for Chronic Conditions (UK)","year":"2006"},{"key":"2022071421521546600_euab262-B14","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/europace\/eul097","article-title":"ACC\/AHA\/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society","volume":"8","author":"Fuster","year":"2006","journal-title":"Europace"},{"key":"2022071421521546600_euab262-B15","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1161\/CIR.0000000000000665","article-title":"2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS Guideline for the Management of Patients With Atrial Fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons","volume":"140","author":"January","year":"2019","journal-title":"Circulation"},{"key":"2022071421521546600_euab262-B16","first-page":"1764","article-title":"Safety and efficacy of dronedarone from clinical trials to real-world evidence: implications for its use in atrial fibrillation","volume":"21","author":"Boriani","year":"2019","journal-title":"Europace"},{"key":"2022071421521546600_euab262-B17","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1540-8167.2010.01764.x","article-title":"A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study","volume":"21","author":"Le Heuzey","year":"2010","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2022071421521546600_euab262-B18","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.clinthera.2014.07.013","article-title":"Efficacy of dronedaroneversus propafenone in the maintenance of sinus rhythm in patients with atrial fibrillation after electrical cardioversion","volume":"36","author":"Chun","year":"2014","journal-title":"Clin Ther"},{"key":"2022071421521546600_euab262-B19","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.amjcard.2020.08.026","article-title":"Outcomes associated with dronedarone use in patients with atrial fibrillation","volume":"135","author":"Goehring","year":"2020","journal-title":"Am J Cardiol"},{"key":"2022071421521546600_euab262-B20","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ahj.2018.06.018","article-title":"Ventricular arrhythmia and death among atrial fibrillation patients using anti-arrhythmic drugs","volume":"205","author":"Friberg","year":"2018","journal-title":"Am Heart J"},{"key":"2022071421521546600_euab262-B21","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ijcard.2018.11.133","article-title":"Impact of dronedarone on the risk of myocardial infarction and stroke in atrial fibrillation patients followed in general practices in Germany","volume":"278","author":"Ehrlich","year":"2019","journal-title":"Int J Cardiol"},{"key":"2022071421521546600_euab262-B22","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ijcard.2018.04.007","article-title":"Dronedarone, amiodarone and other antiarrhythmic drugs, and acute liver injuries: a case-referent study","volume":"266","author":"Grimaldi-Bensouda","year":"2018","journal-title":"Int J Cardiol"},{"key":"2022071421521546600_euab262-B23","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1056\/NEJMoa0800456","article-title":"Increased mortality after dronedarone therapy for severe heart failure","volume":"358","author":"K\u00f8ber","year":"2008","journal-title":"N Engl J Med"},{"key":"2022071421521546600_euab262-B24","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/978-94-010-9772-7_2","volume-title":"Side-Effects of Anti-Inflammatory Drugs","author":"Weber","year":"1987"}],"container-title":["EP Europace"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/europace\/article-pdf\/24\/6\/899\/44890739\/euab262.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/europace\/article-pdf\/24\/6\/899\/44890739\/euab262.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T21:53:13Z","timestamp":1657835593000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/europace\/article\/24\/6\/899\/6430919"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,18]]},"references-count":24,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,11,18]]},"published-print":{"date-parts":[[2022,7,15]]}},"URL":"https:\/\/doi.org\/10.1093\/europace\/euab262","relation":{},"ISSN":["1099-5129","1532-2092"],"issn-type":[{"value":"1099-5129","type":"print"},{"value":"1532-2092","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,6,1]]},"published":{"date-parts":[[2021,11,18]]}}}